source
- BioNTech's HER2-directed ADC shows modest benefit and higher lung toxicity in phase 3 trialBioNTech reported results of its phase 3 DYNASTY-Breast02 trial evaluating trastuzumab pamirtecan (t-pam), an HER2-directed antibody-drug conjugate, in patients with HR-positive, HER2-low metastati…
- Corxel opts for SPAC merger to take oral obesity drug public on NasdaqCorxel Pharmaceuticals, an obesity-focused biotech, said it will merge with Amanat Acquisition in the first half of next year to become a publicly traded company on Nasdaq. The company’s CFO noted…